



ROGEL CANCER CENTER
UNIVERSITY OF MICHIGAN HEALTH



—CME ACCREDITED—

MICHIGAN MEDICINE

UPDATES IN BREAST CANCER MANAGEMENT SYMPOSIUM

Saturday, September 6, 2025

8:00 AM – 4:00 PM

Vanguard Hotel
201 Glen Avenue
Ann Arbor, MI 48104



Scan to register



Keynote speaker:
Ben Ho Park, MD, PhD
Vanderbilt-Ingram Cancer Center

In partnership with:



MORNING SESSION

8:00 am: **Breakfast and Networking**

WELCOME AND INTRODUCTIONS

8:40 am: **Erin Cobain, MD; Monika Burness, MD;**
Melissa Pilewskie, MD
University of Michigan Health Rogel Cancer Center

CLINICAL QUESTIONS IN THE MANAGEMENT OF EARLY STAGE BREAST CANCER

9:00 am: **Optimal Management of the Axilla in 2025**
Melissa Pilewskie, MD; University of Michigan Health
Rogel Cancer Center

9:30 am: **Recent Advances and Updates in Radiation
Oncology for Breast Cancer**
Corey Speers, MD, PhD; University of Alabama at Birmingham

10:00 am: **Important Considerations in the Management of
Breast Cancer in Young Women**
Adrienne Waks, MD; Dana Farber Cancer Institute

10:30 am: **Panel Discussion, Early Stage Breast Cancer**

10:50 am: **Coffee and Networking**

11:05 am: **Germline Breast Cancer Risk: Clinical Implications
and Knowledge Gaps**
Payal Shah, MD; Abramson Cancer Center Hospital of
the University of Pennsylvania

11:35 am: **Managing Toxicities of Breast Cancer Therapies**
N. Lynn Henry, MD, PhD; University of Michigan Health
Rogel Cancer Center



MICHIGAN MEDICINE UPDATES IN BREAST CANCER MANAGEMENT SYMPOSIUM

Saturday, September 6, 2025



Target Audience

This symposium is intended for nurses, physicians, physicians in training, (residents/fellows), medical students, nurse practitioners, other Healthcare professional, physician assistant, physician Resident, scientists and advanced practice providers in managing breast cancer patients

Activity Description

The Michigan Medicine Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ~10M residents, and ~750 community medical oncologists. The Mission of the UMRCC is to reduce the burden of cancer and advance health equity through transdisciplinary collaboration in research, education, patient care and community outreach.

Objectives

Upon completion of this program, the participant will:
1) Understand recent paradigm shifts in locoregional therapy recommendations for patients with early[1]stage breast cancer. 2) Appreciate the rapidly evolving therapeutic landscape across the spectrum of breast cancers, including the increasing utilization of novel therapies. 3) Identify impactful research findings, specifically with regards to use of circulating tumor DNA to monitor disease status or detect therapeutically relevant genomic alterations.

Faculty Planners

Erin Cobain, MD
Monika Burness, MD
Melissa Pilewskie, MD

Financial Disclosure Information

Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

No cost to attend.

AFTERNOON SESSION

12:05 pm: **Lunch**

12:45 pm: **Keynote Address - ctDNA to Guide Breast Cancer Therapies: the Breast is Yet to Come**
Ben Ho Park, MD, PhD; Vanderbilt-Ingram Cancer Center

CLINICAL QUESTIONS IN THE MANAGEMENT OF METASTATIC BREAST CANCER

1:45 pm: **First-line Therapy for Metastatic HER2-Positive Breast Cancer**
Hadeel Assad, MD; Wayne State University

2:15 pm: **First-line Therapy for Metastatic Triple Negative Breast Cancer**
Monika Burness, MD; University of Michigan Health Rogel Cancer Center

2:45 pm: **Optimal Treatment Strategies for CDK4/6 Inhibitor Resistant Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer**
Erin Cobain, MD; University of Michigan Health Rogel Cancer Center

3:15 pm: **Panel Discussion, Metastatic Breast Cancer**

4:00 pm: **Closing Remarks**

Accreditation and Credit Designation The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.